|
| Author (year) | Clot extent | Antibiotic regimen | Anticoagulation agent | Anticoagulation duration | Outcomes |
|
| Presented case | PV and SMV | I: vancomycin and meropenem
F: ertapenem (2 weeks) | UFH and apixaban | 3 months | Recovery and elective sigmoidectomy 2 years later |
| Abdallah et al. (2020) | PV, SMV, and IMV | I: meropenem
F: ertapenem (1 month) | UFH and warfarin | 6 months | Recovery and asymptomatic at 6-month follow-up |
| Hamera et al. (2019) | PV | I: meropenem
F: ceftriaxone/metronidazole (1 month) | Enoxaparin | 1 month | Recovery and no long-term follow-up |
| Le Roux et al. (2006) | SMV | F: amoxicillin-clavulanate and metronidazole (10 months) | UFH | Hospitalization | Recovery, 10-month follow-up, and abdominal US with chronic PVT |
| Mellor et al. (2017) | IMV | I: piperacillin-tazobactam
F: ertapenem (1 month) | UFH | Hospitalization | Recovery, 1-month follow-up, and CT with PVT resolution |
| Moore et al. (2016) | Right PV | I: piperacillin-tazobactam
F: metronidazole (4 weeks) | Enoxaparin and warfarin | 6 months | Recovery and asymptomatic at follow-up |
| Radovanovic et al. (2019) | PV | I: ceftriaxone/metronidazole
F: amoxicillin-clavulanate (2 weeks) | Enoxaparin and warfarin | 3 months | Recovery and asymptomatic at 1-month follow-up |
| Rahmati et al. (2017) | PV | I: ertapenem
F: ceftriaxone/metronidazole (2 months), ampicillin-clavulanate (2 months) | Enoxaparin | — | Recovery and 4-month follow-up CT with cavernous PV transformation |
| Tharu and et al. (2020) | Superior right hepatic vein | I: vancomycin/ceftriaxone/metronidazole
F: ceftriaxone/metronidazole (6 weeks) | None | — | Recovery and 1-month CT with PVT resolution |
| Akhrass et al. (2015) | Main PV at the confluence | I: piperacillin-tazobactam
F: Clindamycin (6 weeks) | UFH and warfarin | 6 weeks | Recovery and follow-up not reported |
| Zheng et al. (2014) | Right hepatic vein | I: cefepime
F: clindamycin | Enoxaparin and warfarin | — | Recovery and 2-month follow-up |
| Hamidi et al. (2008) case 1 | SMV | I: amoxicillin-clavulanate (during admission)
F: — | LMWH and fluindione | 6 months | Recovery and 5-month follow-up US with PVT resolution |
| Hamidi et al. (2008) case 2 | SMV | None | None | None | Left against medical advice |
| Soo et al. (1999) | PV andSMV | I: ciprofloxacin/metronidazole/penicillin
F: amoxicillin-clavulanate/metronidazole (6 weeks) | UFH and warfarin | 6 months | Recovery and 4-month MRI with resolved PVT |
| Shahani et al. (2011) | Left and right PV, SMV, and splenic vein | I: vancomycin/meropenem
F: tigecycline (4 weeks) | None | None | Recovery and 2-month CT with cavernous PV transformation |
| Clarke et al. (2003) | PV and SMV | F: benzylpenicillin/metronidazole/ciprofloxacin (6 weeks) | UFH and warfarin | Indefinite | Recovery and 7-weeks US with PVT improvement |
| Redford et al. (2005) | PV | I: metronidazole/benzylpenicillin
F: clindamycin (5 weeks) | LMWH and warfarin | 3 months | Recovery and 3-months follow-up |
| Bultink et al. (1999) | PV | I: imipenem
F: penicillin G (6 weeks) | IV heparin | Hospitalization | Recovery and 2-month US with chronic PVT |
| Verna et al. (2004) | Left PV | F: clindamycin (2 weeks) | None | None | Recovery and 6-month CT with chronic PVT and left hepatic atrophy |
| El Braks et al. (2004) | PV and SMV | F: piperacillin-tazobactam (2 weeks) and ofloxacin (3 weeks) | UFH and fluindione | 9 months | Recovery and CT at follow-up (not reported) with chronic PVT |
| Etienne et al. (2001) | PV | F: cefotaxime and metronidazole (2 weeks) and metronidazole (2 weeks) | LMWH | 3 weeks | Recovery and 5-week US with resolution |
| Schweigart et al. (2005) | PV | F: clindamycin | Warfarin | Indefinitely | Recovery and no long-term follow-up |
|
